Scholarlink

Purpose <p>Maternal attention-deficit/hyperactivity disorder (ADHD) is increasingly recognised during the reproductive years, often with delayed diagnosis. Although ADHD has been linked to perinatal complications, it remains unclear whether risks reflect ADHD itself, comorbidity, vulnerability, behaviours, and medication use. We examined associations between maternal ADHD, stratified by diagnosis before and after childbirth, and ADHD medication exposure during pregnancy with a range of pregnancy, childbirth, and neonatal outcomes.</p> Methods <p>We conducted a nationwide register-based cohort study, including 741,905 singleton live births in Denmark (2010–2022). Childbirths were classified by maternal ADHD diagnosis before childbirth (<i>n</i> = 12,859), after childbirth (<i>n</i> = 15,683), and no ADHD (<i>n</i> = 713,363). Among women diagnosed before childbirth, ADHD medication exposure was classified; no exposure (<i>n</i> = 10,118), first-trimester (<i>n</i> = 1,129) and continued (<i>n</i> = 1,612) based on prescription-timing. Analyses were preformed using Poisson GEE, accounting for repeated births and adjusting for sociodemographics, psychiatric history, and somatic comorbidity.</p> Results <p>Maternal ADHD diagnosed before childbirth was associated with preterm childbirth (aRR 1.13, 95% CI 1.04–1.22; aRR 1.29, 95% CI 1.07–1.56) and low birthweight (aRR 1.19, 95% CI 1.09–1.30). Early pregnancy haemorrhage was modestly elevated for ADHD diagnosed before and after childbirth (aRR 1.15, 95% CI 1.08–1.25; aRR 1.14, 95% CI 1.07–1.22). ADHD diagnosed after childbirth was associated with infection (aRR 1.19, 95% CI 1.11–1.27), hyperemesis (aRR 1.23, 95% CI 1.13–1.34), and Apgar score &lt; 7) (moderate aRR 1.48, 95% CI 1.09–2.01; severe aRR 1.32, 95% CI 1.09–1.59). ADHD medication in pregnancy (vs. unmedicated) was associated with gestational hypertension (first-trimester aRR 1.57, 95% CI 1.21–2.02; continued aRR 1.39, 95% CI 1.01–1.91).</p> Conclusion <p>Maternal ADHD, whether diagnosed before childbirth or postpartum, was associated with small increases in selected obstetric and neonatal risks after adjustment for relevant sociodemographic and clinical factors. Continued use of ADHD medication was significantly associated with gestational hypertension only. However, these findings should be interpreted with caution due to the potential for residual confounding, including confounding by indication.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the association between maternal attention-deficit/hyperactivity disorder and obstetric complications: a danish population-based register study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月8日

查看全文
  • Mette Winther,
  • Rikke Damkjaer Maimburg,
  • Sarah Kittel-Schneider,
  • Louise Bøttcher,
  • Kathrine Bang Madsen

摘要

Purpose

Maternal attention-deficit/hyperactivity disorder (ADHD) is increasingly recognised during the reproductive years, often with delayed diagnosis. Although ADHD has been linked to perinatal complications, it remains unclear whether risks reflect ADHD itself, comorbidity, vulnerability, behaviours, and medication use. We examined associations between maternal ADHD, stratified by diagnosis before and after childbirth, and ADHD medication exposure during pregnancy with a range of pregnancy, childbirth, and neonatal outcomes.

Methods

We conducted a nationwide register-based cohort study, including 741,905 singleton live births in Denmark (2010–2022). Childbirths were classified by maternal ADHD diagnosis before childbirth (n = 12,859), after childbirth (n = 15,683), and no ADHD (n = 713,363). Among women diagnosed before childbirth, ADHD medication exposure was classified; no exposure (n = 10,118), first-trimester (n = 1,129) and continued (n = 1,612) based on prescription-timing. Analyses were preformed using Poisson GEE, accounting for repeated births and adjusting for sociodemographics, psychiatric history, and somatic comorbidity.

Results

Maternal ADHD diagnosed before childbirth was associated with preterm childbirth (aRR 1.13, 95% CI 1.04–1.22; aRR 1.29, 95% CI 1.07–1.56) and low birthweight (aRR 1.19, 95% CI 1.09–1.30). Early pregnancy haemorrhage was modestly elevated for ADHD diagnosed before and after childbirth (aRR 1.15, 95% CI 1.08–1.25; aRR 1.14, 95% CI 1.07–1.22). ADHD diagnosed after childbirth was associated with infection (aRR 1.19, 95% CI 1.11–1.27), hyperemesis (aRR 1.23, 95% CI 1.13–1.34), and Apgar score < 7) (moderate aRR 1.48, 95% CI 1.09–2.01; severe aRR 1.32, 95% CI 1.09–1.59). ADHD medication in pregnancy (vs. unmedicated) was associated with gestational hypertension (first-trimester aRR 1.57, 95% CI 1.21–2.02; continued aRR 1.39, 95% CI 1.01–1.91).

Conclusion

Maternal ADHD, whether diagnosed before childbirth or postpartum, was associated with small increases in selected obstetric and neonatal risks after adjustment for relevant sociodemographic and clinical factors. Continued use of ADHD medication was significantly associated with gestational hypertension only. However, these findings should be interpreted with caution due to the potential for residual confounding, including confounding by indication.